EGFR inhibitor-related skin toxicities are evaluated by the Common Terminology Criteria for Adverse Events (CTCAE) (Table 2) and Dermatology Life Quality Index, and in the case of paronychia, SPOT [85] can be useful for evaluating how the symptoms affect the patient’s QOL. Here, EGFR is linked to paronychia.